Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of sevasemten in Becker muscular dystrophy
NL-OMON60674Phase 2Active, not recruiting
- Sponsor
- Edgewise Therapeutics
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sevasemten in Becker muscular dystrophy (BMD), sponsored by Edgewise Therapeutics. Primary endpoint: Incidence, frequency, and severity of treatment-emergent adverse events and serious adverse events. Started Feb 2024; status: active, not recruiting.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NL-OMON60674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60674.